Novartis lowered a major inherited heart-risk marker by 78%. Why did patients not benefit?
Novartis cut Lp(a) by 78% with pelacarsen but failed to reduce cardiovascular events, raising the stakes for Amgen and Eli Lilly.
Pharma & Biotech